Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

C14:2 Tetradecadienoyl (acylcarnitine)

Immunology & Autoimmune

C14:2Tetradecadienoylcarnitine

Review status

Currently under review

Pending specialist review and validation.

What it shows

This test measures C14:2 tetradecadienoylcarnitine, a long‑chain acylcarnitine found in blood. Acylcarnitines are compounds your body makes as it breaks down fats for energy inside mitochondria. Measuring specific acylcarnitines helps show how well certain fat oxidation steps are working.

C14:2 is typically assessed as part of an acylcarnitine profile using tandem mass spectrometry on plasma or a dried blood spot. Doctors use it to evaluate for inborn errors of metabolism that affect long‑chain fat processing and to monitor people with known metabolic conditions.

Why it matters

Abnormal C14:2 levels can point to problems in the pathway that burns long‑chain fats for energy. Conditions such as very long‑chain acyl‑CoA dehydrogenase deficiency or related fatty acid oxidation disorders may show characteristic changes in this marker along with others. Identifying these patterns can explain symptoms like low energy, muscle pain during illness or exercise, or unexpected low blood sugar.

Your clinician may order this test for a newborn after screening results, during an acute illness, before anesthesia, or to monitor known disease. Results can guide nutrition and treatment plans, such as avoiding prolonged fasting, adjusting fat intake, and planning emergency care during infections.

Understanding your results

Your result is interpreted together with other acylcarnitines, your age, symptoms, and clinical history. A higher than expected C14:2 may prompt repeat testing, a full acylcarnitine profile, urine organic acids, and possibly genetic testing to confirm or rule out a fatty acid oxidation disorder. If you feel well and the rest of your profile is reassuring, your clinician may simply recheck at a later time or during illness.

A normal result does not completely exclude metabolic conditions, since some disorders show clearer changes during stress or fasting. Diet, supplements, and some medicines can influence the profile. Your care team will explain what your result means for you and whether any follow‑up, diet changes, or family testing is recommended.

Reference ranges

00.09 umol/L
All sexes
0 days – 7 days
00.08 umol/L
All sexes
7 days – 1 month
00.07 umol/L
All sexes
1 month – 12 months
00.06 umol/L
All sexes
12 months – 13 years
00.08 umol/L
All sexes
13 years – 19 years
00.09 umol/L
All sexes
19 years – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact C14:2 Tetradecadienoyl (acylcarnitine)

  • Fasting and illness

    Levels can shift during prolonged fasting, fever, or catabolic stress, which increases fat breakdown and may unmask fatty acid oxidation defects.

  • Diet and supplements

    High intake of long‑chain fats, use of medium‑chain triglyceride formulas, or carnitine supplements can influence acylcarnitine patterns in blood.

  • Medications and cofactors

    Certain medicines, especially some antiepileptics, and riboflavin status can alter acylcarnitine profiles. Always list your medications and vitamins.

  • Sample type and timing

    Plasma versus dried blood spot, non‑fasting collection, hemolysis, or delays in processing can affect results and may prompt repeat testing.

  • Newborn and prematurity effects

    Transitional metabolism in the first weeks of life and prematurity can cause variability. Interpretation uses age‑specific expectations.

  • Pregnancy and postpartum

    Physiologic changes in pregnancy can lower carnitine stores and subtly change acylcarnitines, so context and clinical history are important.

2026

References

  1. McGill University Health Centre. (2019, June 07). C14:2 Tetradecadienoyl (Task CD 709475). Laboratory reference ranges.
  2. American College of Medical Genetics and Genomics. (2020). ACT Sheet: Elevated long‑chain acylcarnitines suggestive of very long‑chain acyl‑CoA dehydrogenase deficiency.
  3. Vockley, J., Burton, B. K., Berry, G. T., Longo, N., Phillips, J., Sanchez‑Valle, A., Tanpaiboon, P., & Chapman, K. A. (2019). Recommendations for the diagnosis and management of long‑chain fatty acid oxidation disorders. Genetics in Medicine, 21(9), 1904–1925.